Drug Development

Protocols: Indivior claims PhIII success, points to 2017 FDA OK; InVivo touts another patient response in spinal study

The UK’s Indivior (LON: INDV) got a boost today after announcing that its Phase III study of a monthly dose of buprenorphine was positive. The biotech says that based on its conversations with the FDA, the company may get a green light for this therapy by the end of next year. The monthly dosing is intended to assist patients who are being treated for opioid abuse, making a relapse less likely.

Cambridge, MA-based InVivo Therapeutics’ stock $NVIV got a boost on its latest release touting the 5th case where its implant of the Neuro-Spinal Scaffold was linked to an upgrade in a patient’s condition. The 9th patient implanted was upgraded from a complete spinal cord injury to an incomplete injury. Its shares jumped 10%.

New York-based Rasna Therapeutics has executed a reverse merger, landing on the OTC exchange. The little biotech is working on new therapies for leukemia.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Director/Sr Director, Oncology/Immuno-Oncology
Aro Biotherapeutics Company Denver, CO
Director/Sr. Director Oncology
Aro BioTx Philadelphia, PA
Manufacturing Associate – Upstream
Molecular Templates Austin, TX
Scientist, Process Development
Molecular Templates Austin, TX
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->